Skip to search formSkip to main contentSkip to account menu

femoston

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Drug CombinationsDydrogesteroneEstradiol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Clinical Efficacy and Safety of Femoston in the Treatment of Menstrual Disorder
objective: to analyze clinical curative effect and safety of Femoston in the treatment of menstrual disorder. Methods: 80 cases… 
2015
2015
Application of Femoston after missed abortion curettage Femoston
Objective:To observe the clinic effect of administering Femoston after missed abortion curettage.Methods:One hundred and sixty… 
2015
2015
Application of Femoston in prevention of intrauterine adhesion after high-risk induced abortion
Objective:To explore the clinical effects of applying Femoston in preventing intrauterine adhesion after high-risk induced… 
2011
2011
[Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy].
Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of… 
2011
2011
LE MÉDICAMENT DU MOIS Femoston® Low (0,5 mg d'estradiol plus 2,5 mg de dydrogestérone) comme traitement hormonal de substitution à la ménopause
La combinaison Femoston ® Low est un traitement hormonal de substitution comportant de faibles doses de steroides, a savoir 0,5… 
2009
2009
EFFICACY OF TESTOSTERONE THERAPY DELIVERED BY PELLET IMPLANT
2006
2006
Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile.
2001
2001
[Effect of the treatment with femoston on the cardiovascular system in postmenopausal women].
AIM To assess femoston effects on the cardiovascular system in postmenopause. MATERIAL AND METHODS Cardiovascular effects of… 
2000
2000
[Vasoactive effects of femostone in women with metabolic postmenopausal syndrome].
The metabolic postmenopausal syndrome (MPS) is characterized by a complex of metabolic disorders: lipid (76%), purin (56… 
1996
1996
Endometrial safety of Femoston
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)